Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

Darapladib for preventing ischemic events in stable coronary heart disease.

STABILITY Investigators, White HD, Held C, Stewart R, Tarka E, Brown R, Davies RY, Budaj A, Harrington RA, Steg PG, Ardissino D, Armstrong PW, Avezum A, Aylward PE, Bryce A, Chen H, Chen MF, Corbalan R, Dalby AJ, Danchin N, De Winter RJ, Denchev S, Diaz R, Elisaf M, Flather MD, Goudev AR, Granger CB, Grinfeld L, Hochman JS, Husted S, Kim HS, Koenig W, Linhart A, Lonn E, López-Sendón J, Manolis AJ, Mohler ER 3rd, Nicolau JC, Pais P, Parkhomenko A, Pedersen TR, Pella D, Ramos-Corrales MA, Ruda M, Sereg M, Siddique S, Sinnaeve P, Smith P, Sritara P, Swart HP, Sy RG, Teramoto T, Tse HF, Watson D, Weaver WD, Weiss R, Viigimaa M, Vinereanu D, Zhu J, Cannon CP, Wallentin L.

N Engl J Med. 2014 May 1;370(18):1702-11. doi: 10.1056/NEJMoa1315878. Epub 2014 Mar 30.

2.

Persistent lipid abnormalities in statin-treated patients with diabetes mellitus in Europe and Canada: results of the Dyslipidaemia International Study.

Leiter LA, Lundman P, da Silva PM, Drexel H, Jünger C, Gitt AK; DYSIS investigators.

Diabet Med. 2011 Nov;28(11):1343-51. doi: 10.1111/j.1464-5491.2011.03360.x.

PMID:
21679231
3.

Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.

Tardif JC, Ponikowski P, Kahan T; ASSOCIATE Study Investigators.

Eur Heart J. 2009 Mar;30(5):540-8. doi: 10.1093/eurheartj/ehn571. Epub 2009 Jan 9.

4.

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.

Meltzer HY, Arvanitis L, Bauer D, Rein W; Meta-Trial Study Group.

Am J Psychiatry. 2004 Jun;161(6):975-84.

PMID:
15169685
5.

Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study.

Sechter D, Peuskens J, Fleurot O, Rein W, Lecrubier Y; Amisulpride Study Group.

Neuropsychopharmacology. 2002 Dec;27(6):1071-81. Erratum in: Neuropsychopharmacology. 2003 Mar;28(3):611.

6.

Dose-related effects of amisulpride on five dimensions of psychopathology in patients with acute exacerbation of schizophrenia.

Müller MJ, Wetzel H, Eich FX, Rein W, Puech A, Benkert O; Amisulpride Study Group.

J Clin Psychopharmacol. 2002 Dec;22(6):554-60.

PMID:
12454554
7.

A double-blind, randomised comparative trial of amisulpride versus olanzapine in the treatment of schizophrenia: short-term results at two months.

Martin S, Lĵo H, Peuskens J, Thirumalai S, Giudicelli A, Fleurot O, Rein W; SOLIANOL Study Group.

Curr Med Res Opin. 2002;18(6):355-62.

PMID:
12442883
8.

Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group.

Colonna L, Saleem P, Dondey-Nouvel L, Rein W.

Int Clin Psychopharmacol. 2000 Jan;15(1):13-22.

PMID:
10836281
9.

Safety profile of amisulpride in short- and long-term use.

Rein W, Coulouvrat C, Dondey-Nouvel L.

Acta Psychiatr Scand Suppl. 2000;400:23-7. Review.

PMID:
10823308
10.

Amisulpride vs. risperidone in the treatment of acute exacerbations of schizophrenia. Amisulpride study group.

Peuskens J, Bech P, Möller HJ, Bale R, Fleurot O, Rein W.

Psychiatry Res. 1999 Nov 8;88(2):107-17.

PMID:
10622347
11.
13.

Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology -- a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like antagonist. The Amisulpride Study Group.

Wetzel H, Gründer G, Hillert A, Philipp M, Gattaz WF, Sauer H, Adler G, Schröder J, Rein W, Benkert O.

Psychopharmacology (Berl). 1998 Jun;137(3):223-32.

PMID:
9682999
14.

[French translation of the Frankfurt Complaint Questionnaire (Frankfurter Beschwerde-Fragebogen, FBF, Süllwold, 1986)].

Loas G, Berner P, Rein W, Yon V, Boyer P, Lecrubier Y.

Encephale. 1997 Sep-Oct;23(5):364-74. French.

PMID:
9453929
15.

Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. PROD-ASLP Study Group.

Möller HJ, Boyer P, Fleurot O, Rein W.

Psychopharmacology (Berl). 1997 Aug;132(4):396-401.

PMID:
9298518
16.

Clinical update on amisulpride in deficit schizophrenia.

Rein W, Turjanski S.

Int Clin Psychopharmacol. 1997 May;12 Suppl 2:S19-27. Review.

PMID:
9218164
17.

Amisulpride versus imipramine and placebo in dysthymia and major depression. Amisulpride Study Group.

Lecrubier Y, Boyer P, Turjanski S, Rein W.

J Affect Disord. 1997 Apr;43(2):95-103.

PMID:
9165379
18.

Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia.

Loo H, Poirier-Littre MF, Theron M, Rein W, Fleurot O.

Br J Psychiatry. 1997 Jan;170:18-22.

PMID:
9068769
19.

[Methodological constraints in evaluating anti-deficit effects].

Boyer P, Lecrubier Y, Rein W.

Encephale. 1996 Jun;22 Spec No 2:25-7. Review. French.

PMID:
8767038
20.

[Changes in slow evoked potentials in depressed patients treated with amitriptyline and oxaprotiline].

Giedke H, Heimann H, Rein W.

Rev Electroencephalogr Neurophysiol Clin. 1987 Sep;17(3):279-87. French.

PMID:
3685573

Supplemental Content

Loading ...
Support Center